163 related articles for article (PubMed ID: 28992104)
41. Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay.
Heywood WE; Galimberti D; Bliss E; Sirka E; Paterson RW; Magdalinou NK; Carecchio M; Reid E; Heslegrave A; Fenoglio C; Scarpini E; Schott JM; Fox NC; Hardy J; Bhatia K; Heales S; Sebire NJ; Zetterberg H; Mills K
Mol Neurodegener; 2015 Dec; 10():64. PubMed ID: 26627638
[TBL] [Abstract][Full Text] [Related]
42. HOTMAQ: A Multiplexed Absolute Quantification Method for Targeted Proteomics.
Zhong X; Yu Q; Ma F; Frost DC; Lu L; Chen Z; Zetterberg H; Carlsson C; Okonkwo O; Li L
Anal Chem; 2019 Feb; 91(3):2112-2119. PubMed ID: 30608134
[TBL] [Abstract][Full Text] [Related]
43. Induced Pluripotent Stem Cell-Derived Astroglia: A New Tool for Research Towards the Treatment of Alzheimer's Disease.
Atkinson-Dell R; Mohamet L
Adv Exp Med Biol; 2019; 1175():383-405. PubMed ID: 31583596
[TBL] [Abstract][Full Text] [Related]
44. Effect of Honokiol on culture time and survival of Alzheimer's disease iPSC-derived neurons.
Le DTT; Vu CM; Ly TTB; Nguyen NT; Nguyen PTM; Chu HH
Bioimpacts; 2024; 14(1):27652. PubMed ID: 38327632
[TBL] [Abstract][Full Text] [Related]
45. Integrated analysis of mRNA, microRNA and protein in systemic lupus erythematosus-specific induced pluripotent stem cells from urine.
Tang D; Chen Y; He H; Huang J; Chen W; Peng W; Lu Q; Dai Y
BMC Genomics; 2016 Jul; 17():488. PubMed ID: 27402083
[TBL] [Abstract][Full Text] [Related]
46. Modeling Cystic Fibrosis Using Pluripotent Stem Cell-Derived Human Pancreatic Ductal Epithelial Cells.
Simsek S; Zhou T; Robinson CL; Tsai SY; Crespo M; Amin S; Lin X; Hon J; Evans T; Chen S
Stem Cells Transl Med; 2016 May; 5(5):572-9. PubMed ID: 27034411
[TBL] [Abstract][Full Text] [Related]
47. Defining pluripotent stem cells through quantitative proteomic analysis.
Reiland S; Salekdeh GH; Krijgsveld J
Expert Rev Proteomics; 2011 Feb; 8(1):29-42. PubMed ID: 21329426
[TBL] [Abstract][Full Text] [Related]
48. Discovery and Subsequent Confirmation of Novel Serum Biomarkers Diagnosing Alzheimer's Disease.
Shah DJ; Rohlfing F; Anand S; Johnson WE; Alvarez MT; Cobell J; King J; Young SA; Kauwe JS; Graves SW
J Alzheimers Dis; 2016; 49(2):317-27. PubMed ID: 26484917
[TBL] [Abstract][Full Text] [Related]
49. A novel liquid chromatography/tandem mass spectrometry method for the quantification of glycine as biomarker in brain microdialysis and cerebrospinal fluid samples within 5min.
Voehringer P; Fuertig R; Ferger B
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Nov; 939():92-7. PubMed ID: 24121745
[TBL] [Abstract][Full Text] [Related]
50. Induced pluripotent stem cells as a discovery tool for Alzheimer׳s disease.
Sullivan SE; Young-Pearse TL
Brain Res; 2017 Feb; 1656():98-106. PubMed ID: 26459988
[TBL] [Abstract][Full Text] [Related]
51. Cell-Based Assays Using Differentiated Human Induced Pluripotent Cells.
Cader Z; Graf M; Burcin M; Mandenius CF; Ross JA
Methods Mol Biol; 2019; 1994():1-14. PubMed ID: 31124100
[TBL] [Abstract][Full Text] [Related]
52. Differentiation of primordial germ cells from induced pluripotent stem cells of primary ovarian insufficiency.
Leng L; Tan Y; Gong F; Hu L; Ouyang Q; Zhao Y; Lu G; Lin G
Hum Reprod; 2015 Mar; 30(3):737-48. PubMed ID: 25586786
[TBL] [Abstract][Full Text] [Related]
53. Engineering personalized neural tissue by combining induced pluripotent stem cells with fibrin scaffolds.
Montgomery A; Wong A; Gabers N; Willerth SM
Biomater Sci; 2015 Feb; 3(2):401-13. PubMed ID: 26218131
[TBL] [Abstract][Full Text] [Related]
54. [Application of mass spectrometry-based chromatographic technologies in the diagnosis of Alzheimer's disease].
Wang D; Xin G; Shi Z; Chen J; Li P
Se Pu; 2011 Apr; 29(4):293-7. PubMed ID: 21770236
[TBL] [Abstract][Full Text] [Related]
55. Being human: The role of pluripotent stem cells in regenerative medicine and humanizing Alzheimer's disease models.
Sproul AA
Mol Aspects Med; 2015; 43-44():54-65. PubMed ID: 26101165
[TBL] [Abstract][Full Text] [Related]
56. Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease.
Finehout EJ; Franck Z; Choe LH; Relkin N; Lee KH
Ann Neurol; 2007 Feb; 61(2):120-9. PubMed ID: 17167789
[TBL] [Abstract][Full Text] [Related]
57. Generation of induced pluripotent stem cells (iPSCs) from an Alzheimer's disease patient carrying an A79V mutation in PSEN1.
Li T; Pires C; Nielsen TT; Waldemar G; Hjermind LE; Nielsen JE; Dinnyes A; Hyttel P; Freude KK
Stem Cell Res; 2016 Mar; 16(2):229-32. PubMed ID: 27345973
[TBL] [Abstract][Full Text] [Related]
58. Determination of catecholamines and their metabolites in rat urine by ultra-performance liquid chromatography-tandem mass spectrometry for the study of identifying potential markers for Alzheimer's disease.
Lv C; Li Q; Liu X; He B; Sui Z; Xu H; Yin Y; Liu R; Bi K
J Mass Spectrom; 2015 Feb; 50(2):354-63. PubMed ID: 25800017
[TBL] [Abstract][Full Text] [Related]
59. Changes in the Chemical Barrier Composition of Tears in Alzheimer's Disease Reveal Potential Tear Diagnostic Biomarkers.
Kalló G; Emri M; Varga Z; Ujhelyi B; Tőzsér J; Csutak A; Csősz É
PLoS One; 2016; 11(6):e0158000. PubMed ID: 27327445
[TBL] [Abstract][Full Text] [Related]
60. Generation of induced pluripotent stem cells (iPSCs) from an Alzheimer's disease patient carrying a M146I mutation in PSEN1.
Li T; Pires C; Nielsen TT; Waldemar G; Hjermind LE; Nielsen JE; Dinnyes A; Holst B; Hyttel P; Freude KK
Stem Cell Res; 2016 Mar; 16(2):334-7. PubMed ID: 27345998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
